BiotechTube

G-CSF + Early retreatment with ATG

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aplastic Anaemia

Conditions

Aplastic Anaemia

Trial Timeline

Mar 1, 2001 → Nov 1, 2010

NCT ID
NCT01163942

About G-CSF + Early retreatment with ATG

G-CSF + Early retreatment with ATG is a phase 3 stage product being developed by Sanofi for Aplastic Anaemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01163942. Target conditions include Aplastic Anaemia.

What happened to similar drugs?

1 of 6 similar drugs in Aplastic Anaemia were approved

Approved (1) Terminated (1) Active (5)
🔄Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
🔄hATG + CsA + EltrombopagNovartisPhase 3
✅ICL670 + Chelation + No chelationNovartisApproved
🔄Alectinib + CrizotinibRochePhase 3
🔄PF-06462700PfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01163942Phase 3Terminated

Competing Products

20 competing products in Aplastic Anaemia

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
AlefaceptAstellas PharmaPhase 1
21
RomiplostimKyowa KirinPhase 2/3
38
Lenvatinib 24 mgEisaiPhase 2
27
RomiplostimKyowa KirinPhase 2/3
38
RomiplostimKyowa KirinPhase 2/3
38
AMG531Kyowa KirinPhase 2
35
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
44
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporinJiangsu Hengrui MedicinePhase 2
31
Hetrombopag Olamine Tablet；Ciclosporin Soft CapsuleJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
29
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1/2
32
Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
40
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
PosaconazoleMerckPhase 2
35
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension CohortNovartisPhase 1/2
36